SCHEMBL7024973

SCHEMBL7024973

OC(CCN(Cc1ccccc1)Cc1ccccc1)(c1cccc(Br)c1)c1cccc(Br)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.43
OPRM1 P35372 2/20 0.39
OPRD1 P41143 2/20 0.39
OPRK1 P41145 2/20 0.39
SIGMAR1 Q99720 2/20 0.39
PTGES O14684 1/20 0.39
HDAC3 O15379 2/20 0.38
HDAC1 Q13547 2/20 0.38
HDAC2 Q92769 2/20 0.38
HDAC8 Q9BY41 2/20 0.38
NCOR2 Q9Y618 2/20 0.38
TMEM97 Q5BJF2 1/20 0.38
KIF11 P52732 1/20 0.38
HTT P42858 1/20 0.38
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
CHRM2 P08172 1/20 0.37
CHRM4 P08173 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6320217 0.84 SMN1; SMN2 (0.46) MEN1KMT2ASMN1; SMN2OPRM1OPRD1
SCHEMBL7148205 0.83 MEN1 (0.48) MEN1KMT2ASMN1; SMN2OPRM1OPRD1
SCHEMBL6326374 0.75 SMN1; SMN2 (0.46) MEN1KMT2ASMN1; SMN2OPRK1SIGMAR1
SCHEMBL7032860 0.74 SMN1; SMN2 (0.43) MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL11125959 0.74 SMN1; SMN2 (0.57) MEN1KMT2ASMN1; SMN2OPRK1SIGMAR1
SCHEMBL6320470 0.71 CALM1 (0.47) MEN1KMT2ASMN1; SMN2OPRK1SIGMAR1
SCHEMBL7608480 0.70 L3MBTL1 (0.52) SMN1; SMN2LMNAMAOB
SCHEMBL9906148 0.70 KIF11 (0.44) MEN1KMT2ASMN1; SMN2SIGMAR1KIF11
SCHEMBL14181862 0.70 CALM1 (0.62) MEN1KMT2AOPRK1SIGMAR1PTGES
SCHEMBL15269721 0.70 MEN1 (0.44) MEN1KMT2AOPRM1OPRD1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030032834-A1 Aminoalcohol derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030032834-A1 Aminoalcohol derivatives ADRB1, ADRB2, ADRB3 MEN1 4166/4885KMT2A 3486/4885SMN1; SMN2 3568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.